Helus Pharma director Inamdar holds 224K shares via firm

The October 2025 award includes quarterly vesting dates on November 20, February 20, May 20 and August 20 over three years.

Rhea-AI Filing Summary

Helus Pharma Inc. (HELP) lists director Amir Inamdar’s reported holdings as of October 13, 2026: 224,332 common shares held by Zephyr Life Sciences Ltd., described as a United Kingdom corporation owned and controlled by him, and 3,490 common shares held directly. The disclosed position also includes 66,668 unvested restricted share units from an October 1, 2025 grant; each unit represents a right to receive one common share.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Inamdar Amir

Role Director

Type	Security	Shares	Price	Value
holding	Restricted Share Units F3, F2, F1	--	--	--
holding	Common Shares F1	--	--	--
holding	Common Shares	--	--	--

Holdings After Transaction: Restricted Share Units — 66,668 contracts (Indirect, Held by Zephyr Life Sciences Inc.); Common Shares — 224,332 shares (Indirect, Held by Zephyr Life Sciences Ltd.); Common Shares — 3,490 shares (Direct)

Footnotes (3)

1. F1. Held by Zephyr Life Sciences Ltd., a United Kingdom corporation owned and controlled by the reporting person.
2. F2. On October 1, 2025, the Reporting Person was granted 100,000 restricted share units ("RSUs") which vest as follows: 8,333 RSUs vesting on January 6, 2026, and 8,333 RSUs vesting quarterly over three years on November 20, February 20, May 20, and August 20 until fully vested. As of the date of this Form 3, the Reporting Person holds 66,668 unvested RSUs from the October 2025 grant.
3. F3. Each RSU represents a right to receive one Issuer common share.

Key Figures

Restricted share units granted: 100,000 RSUs Unvested restricted share units: 66,668 RSUs Indirect common shares: 224,332 shares +1 more

4 metrics

Restricted share units granted 100,000 RSUs Granted October 1, 2025.

Unvested restricted share units 66,668 RSUs As of the date of the Form 3; each RSU represents a right to receive one common share.

Indirect common shares 224,332 shares Held by Zephyr Life Sciences Ltd. as of October 13, 2026.

Direct common shares 3,490 shares Held as of October 13, 2026.

Key Terms

restricted share units, unvested RSUs, vesting

3 terms

restricted share units financial

"100,000 restricted share units ("RSUs")"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

unvested RSUs financial

"holds 66,668 unvested RSUs"

vesting financial

"8,333 RSUs vesting quarterly over three years"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many HELP common shares did director Amir Inamdar report?

He reported 224,332 common shares held by Zephyr Life Sciences Ltd. and 3,490 common shares held directly. The footnote describes Zephyr Life Sciences Ltd. as a United Kingdom corporation owned and controlled by him.

How many unvested HELP restricted share units did Amir Inamdar report?

The reported position includes 66,668 unvested restricted share units. Each RSU represents a right to receive one Helus Pharma common share.

What is the vesting schedule for Amir Inamdar’s HELP RSUs?

The 100,000-RSU grant was made October 1, 2025. It includes 8,333 RSUs vesting January 6, 2026, and 8,333 RSUs vesting quarterly over three years on November 20, February 20, May 20 and August 20, until fully vested.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/26/2026 - 11:20 AM EDT Accepted by SEC EDGAR 10/26/2026 - 11:17 AM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Inamdar Amir

(Last) (First) (Middle)

C/O HELUS PHARMA INC.

100 KING STREET WEST, SUITE 5600

(Street)

TORONTO M5X 1C9

(City) (State) (Zip)

ONTARIO, CANADA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
10/13/2026

3. Issuer Name and Ticker or Trading Symbol
Helus Pharma Inc. [ HELP ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Shares	224,332	I	Held by Zephyr Life Sciences Ltd.(1)
Common Shares	3,490	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(2)	(2)	Common Shares	66,668	(3)	I	Held by Zephyr Life Sciences Inc.(1)

Explanation of Responses:

1. Held by Zephyr Life Sciences Ltd., a United Kingdom corporation owned and controlled by the reporting person.

2. On October 1, 2025, the Reporting Person was granted 100,000 restricted share units ("RSUs") which vest as follows: 8,333 RSUs vesting on January 6, 2026, and 8,333 RSUs vesting quarterly over three years on November 20, February 20, May 20, and August 20 until fully vested. As of the date of this Form 3, the Reporting Person holds 66,668 unvested RSUs from the October 2025 grant.

3. Each RSU represents a right to receive one Issuer common share.

	/s/ Amir Inamdar	10/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)